Home

Our Vision: 
Some day no one will believe cancer surgery was once performed without Tumor Paint Technology.
​
Blaze Bioscience, Inc. is a privately held biotechnology company dedicated to improving the lives of cancer patients. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics. Blaze is working to develop Tumor Paint products and related therapeutics.

Surgery is first line therapy for most solid tumor cancers. Tumor Paint products intend to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery.  The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection as well as more precise and complete surgical removal of cancer—while sparing surrounding normal tissue. The first Tumor Paint product candidate, BLZ-100, has been tested in four Phase 1 clinical trials and has demonstrated clinical proof of concept in brain, breast and skin cancers. Additional potential applications of BLZ-100 include prostate, lung, colorectal and other solid tumor cancers.

BLZ-100, an investigational agent, is being evaluated in a Phase 2/3 clinical study in pediatric CNS (central nervous system) tumors.
​